ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
-0.89%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.06B
AUM Growth
+$5.06B
(-7.6%)
Cap. Flow
-$73M
Cap. Flow
% of AUM
-1.44%
Top 10 Holdings %
Top 10 Hldgs %
72.91%
Holding
44
New
1
Increased
20
Reduced
5
Closed
4
Top Buys
| 1 |
Amicus Therapeutics
FOLD
|
$67.7M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$48.9M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$37.2M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$31M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$20.6M |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$160M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$120M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$55.1M |
| 4 |
Praxis Precision Medicines
PRAX
|
$22M |
| 5 |
United Therapeutics
UTHR
|
$14.1M |
Sector Composition
| 1 | Healthcare | 98.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $700M | 13.83% | 2,970,000 -60,000 | -2% | -$14.1M |
|
2
argenx
ARGX
$43.6B
| $479M | 9.48% | 1,265,555 +10,555 | +0.8% | +$4M |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $443M | 8.76% | 9,805,000 +355,000 | +4% | +$16.1M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $399M | 7.88% | 5,000,000 -1,500,000 | -23% | -$120M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $373M | 7.36% | 5,550,555 +225,555 | +4% | +$15.1M |
|
|
6
Amicus Therapeutics
FOLD
$2.34B
| $288M | 5.69% | 26,800,000 +6,300,000 | +31% | +$67.7M |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $272M | 5.38% | 3,284,000 +249,000 | +8% | +$20.6M |
|
|
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
| $270M | 5.33% | 1,525,000 +210,000 | +16% | +$37.2M |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $254M | 5.02% | 3,390,000 +255,000 | +8% | +$19.1M |
|
10
Ascendis Pharma
ASND
$11.8B
| $211M | 4.18% | 2,275,000 +75,000 | +3% | +$6.97M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $198M | 3.92% | 1,360,000 +60,000 | +5% | +$8.75M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $149M | 2.95% | 4,900,000 -85,000 | -2% | -$2.59M |
|
13
Madrigal Pharmaceuticals
MDGL
$9.76B
| $110M | 2.17% | 1,535,000 +110,000 | +8% | +$7.87M |
|
14
Iovance Biotherapeutics
IOVA
$807M
| $102M | 2.01% | 9,220,000 +95,000 | +1% | +$1.05M |
|
15
Kura Oncology
KURA
$686M
| $88M | 1.74% | 4,800,000 | – | – |
|
16
Krystal Biotech
KRYS
$4.27B
| $70.6M | 1.39% | 1,075,000 +70,000 | +7% | +$4.6M |
|
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $68.8M | 1.36% | 6,500,000 +4,625,000 | +247% | +$48.9M |
|
|
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $68.5M | 1.35% | 7,120,000 -130,000 | -2% | -$1.25M |
|
|
19
SPDR S&P Biotech ETF
XBI
$5.07B
| $66.8M | 1.32% | 900,000 -2,150,000 | -70% | -$160M |
|
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $44.7M | 0.88% | 750,000 +520,000 | +226% | +$31M |
|
21
PMV Pharmaceuticals
PMVP
$74.2M
| $44.2M | 0.87% | 3,100,000 +900,000 | +41% | +$12.8M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $42.8M | 0.84% | 2,222,222 +1,722 | +0.1% | +$33.1K |
|
23
Mersana Therapeutics
MRSN
$36.5M
| $34.9M | 0.69% | 7,550,000 +750,000 | +11% | +$3.47M |
|
24
MannKind Corp
MNKD
$1.41B
| $34.7M | 0.69% | 9,100,000 +300,000 | +3% | +$1.14M |
|
25
Monte Rosa Therapeutics
GLUE
$296M
| $32M | 0.63% | 3,311,536 +102 | +0% | +$986 |
|